News
Daxor Corporation Acquires Volumex And Megatope From Its Existing Supplier Along With Glofil To Enhance Existing Suite Of Diagnostics; No Financial Terms Disclosed
25 Mar 24
M&A
Daxor Announces As Of December 31, 2023, Daxor's Net Assets Were $34,010,384 Or $7.08 Per Share, Revenue Increased 31.8% Year On Year For 2023 Versus 2022, Provides Corporate Update In Letter To Shareholders
18 Mar 24
Earnings, News, Management
Daxor Announces Sales To Three New Hospitals Furthering Expansion Of Its User Base
11 Mar 24
News, Contracts
Daxor Announces Two Significant New Customer Transactions With The Co's BVA-100 In January; No Financial Terms Disclosed
12 Feb 24
M&A, News, Contracts
Daxor Corporation Closes Q4 2023 With Growth In New Sales To Hospital Systems And Increased Utilization Of Its BVA-100 Blood Volume Diagnostic Across The U.S. At Existing Accounts
7 Feb 24
Biotech, News, General
Press releases
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
22 Mar 24
Press Releases
Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts
7 Feb 24
Press Releases